Novo Nordisk A/S (NYSE:NVO) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP grew its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 211,866 shares of the company's stock after acquiring an additional 9,885 shares during the quarter. Quantinno Capital Management LP's holdings in Novo Nordisk A/S were worth $18,225,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. M. Kulyk & Associates LLC increased its holdings in Novo Nordisk A/S by 3.9% during the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares during the period. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Tradewinds Capital Management LLC increased its holdings in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock worth $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after acquiring an additional 124 shares during the period. Finally, Indie Asset Partners LLC increased its holdings in shares of Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after acquiring an additional 126 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

NVO traded down $1.81 on Friday, reaching $64.35. 18,941,653 shares of the stock were exchanged, compared to its average volume of 6,562,568. The company's 50-day moving average price is $67.59 and its 200 day moving average price is $84.91. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $288.75 billion, a PE ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion during the quarter. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NVO. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.